2023 Leronlimab vs Maraviroc only patent:
6. The method of claim 1, further comprising supplementing immunomodulatory intervention with maraviroc with PRO 140, wherein the subject was previously treated with maraviroc.
Down under:
FIELD OF THE INVENTION, end of the 1st paragraph:
"The competitive inhibitors of the present invention may be used to inhibit, interrupt, block, mitigate, dampen, slow the progress of, and/or treat inflammation or various other CCR5/CCL5 axis signaling dependent down-stream activities associated with GvHD, autoimmune disorders, infectious agents, chronic inflammation, and cancer."
Potential clinical applications of using the competitive inhibitor of the CCR5 receptor of the present invention to interfere with the CCR5 receptor and the CCL5 ligand axis are numerous. Such potential applications include diseases with an inflammatory component namely, respiratory tract infections (e.g., RSV, SARS), neuroinflammation (e.g., WNV, HSV, CMV), liver infections (e.g., HCV), asthma, autoimmunity (e.g., MS, Lupus, liver disease, psoriasis, Crohn's Disease, Inflammatory bowel disease, etc.), atherosclerosis, angiogenesis and cancer (e.g., prostrate, breast, melanoma, gastric, colon, ovarian, etc.), fibrosis and transplant rejection and GvHD.
__________
The LL direct "advantageous" blow to Maraviroc:
" Also, unlike maraviroc, PRO 140 is shown to have no CCL5 receptor agonist activity when bound to CCR5 with respect to cAMP levels or cell migration. Accordingly, PRO 140 is shown to provide an advantageous contribution to the art and gives rise to new uses for this CCR5 receptor competitive inhibitor to inhibit, interrupt, block, mitigate, dampen, slow the progress of, and/or therapeutically treat conditions resulting, in whole or in part, from the downstream immunomodulatory effects induced by CCL5 ligand binding on the CCL5 receptor."
Drop down to very bottom for Result Figures of LL Vs MVRC
This patent is Maraviroc's downfall of every indication it is dosed in & even being investigated for....
This patent not only shows that we've known since Covid, Leronlimab can do what Maraviroc does, but better.
Documents Leronlimabs MOA is far superior on CCL5/CCR5 axis, than Maraviroc.
Also very importantly, covers LL / combo treatments on @ a minimum, the many diseases & other non-cancer indications listed
https://patents.google.com/patent/US11584797B2/en
...
6. The method of claim 1, further comprising supplementing immunomodulatory intervention with maraviroc with PRO 140, wherein the subject was previously treated with maraviroc.
Down under:
FIELD OF THE INVENTION, end of the 1st paragraph:
"The competitive inhibitors of the present invention may be used to inhibit, interrupt, block, mitigate, dampen, slow the progress of, and/or treat inflammation or various other CCR5/CCL5 axis signaling dependent down-stream activities associated with GvHD, autoimmune disorders, infectious agents, chronic inflammation, and cancer."
Potential clinical applications of using the competitive inhibitor of the CCR5 receptor of the present invention to interfere with the CCR5 receptor and the CCL5 ligand axis are numerous. Such potential applications include diseases with an inflammatory component namely, respiratory tract infections (e.g., RSV, SARS), neuroinflammation (e.g., WNV, HSV, CMV), liver infections (e.g., HCV), asthma, autoimmunity (e.g., MS, Lupus, liver disease, psoriasis, Crohn's Disease, Inflammatory bowel disease, etc.), atherosclerosis, angiogenesis and cancer (e.g., prostrate, breast, melanoma, gastric, colon, ovarian, etc.), fibrosis and transplant rejection and GvHD.
__________
The LL direct "advantageous" blow to Maraviroc:
" Also, unlike maraviroc, PRO 140 is shown to have no CCL5 receptor agonist activity when bound to CCR5 with respect to cAMP levels or cell migration. Accordingly, PRO 140 is shown to provide an advantageous contribution to the art and gives rise to new uses for this CCR5 receptor competitive inhibitor to inhibit, interrupt, block, mitigate, dampen, slow the progress of, and/or therapeutically treat conditions resulting, in whole or in part, from the downstream immunomodulatory effects induced by CCL5 ligand binding on the CCL5 receptor."
Drop down to very bottom for Result Figures of LL Vs MVRC
This patent is Maraviroc's downfall of every indication it is dosed in & even being investigated for....
This patent not only shows that we've known since Covid, Leronlimab can do what Maraviroc does, but better.
Documents Leronlimabs MOA is far superior on CCL5/CCR5 axis, than Maraviroc.
Also very importantly, covers LL / combo treatments on @ a minimum, the many diseases & other non-cancer indications listed
https://patents.google.com/patent/US11584797B2/en
...
4
